Capella BioScience Overview

  • Founded
  • 2014
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Capella BioScience General Information

Description

Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mAbs therapeutics. The company's medicines leverage novel technologies to develop therapeutics for oncology and autoimmune disease, enabling researchers to research the latest medical technology-based drugs.

Contact Information

Website
www.capellabioscience.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Acquirer
Centessa Pharmaceuticals
Primary Office
  • 158-160 North Gower Street
  • London NW1 2ND
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Capella BioScience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 16-Feb-2021 000.00 Completed Clinical Trials - General
4. Later Stage VC 24-Sep-2020 00.00 000.00 0000 Completed Clinical Trials - General
3. Later Stage VC 16-Aug-2019 00.00 000.00 000.00 Completed Clinical Trials - General
2. Early Stage VC (Series A) 03-Apr-2016 $15.7M $18.1M Completed Pre-Clinical Trials
1. Seed Round 22-Dec-2014 $2.35M $2.35M Completed Startup
To view Capella BioScience’s complete valuation and funding history, request access »

Capella BioScience Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
B Shares 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Preference 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Shares 2,171,715 $0.001306 $2.59 $2.59 1x $2.59 1.73%
Seed 1,500,000 $0.001306 $1.31 $1.31 1x $1.31 17.12%
To view Capella BioScience’s complete cap table history, request access »

Capella BioScience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mA
Drug Discovery
London, United Kingdom
000.00
000000&0 000.00

000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat n
0000 000000000
Seattle, WA
00 As of 0000
000.00
0000000000 0 000.00

00000000

is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dol
0000000000000
San Diego, CA
000 As of 0000
00000
000000000 - 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Capella BioScience Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kineta Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000000 Venture Capital-Backed Lebanon, NH 000 00000 000000 - 000 00000
00000000 Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 36 competitors. Get the full list »

Capella BioScience Patents

  • 8

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Capella BioScience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190315876-A1 Antigen binding molecules that bind light Pending 24-Jan-2018 00000000000
JP-2020505465-A Antigen binding molecule that binds to light Pending 24-Jan-2017 00000000000
GB-201820446-D0 Antigen binding molecules that bind light Granted 24-Jan-2017 00000000000
GB-201701194-D0 Antigen binding molecules that bind light Ceased 24-Jan-2017 00000000000
GB-2566389-A Antigen binding molecules that bind light Granted 24-Jan-2017 C07K16/2875 0
To view Capella BioScience’s complete patent history, request access »

Capella BioScience Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Advent Life Sciences Venture Capital Minority 000 0000 000000 0
DCVC Venture Capital Minority 000 0000 000000 0
Farzad Nazem Angel (individual) Minority 000 0000 000000 0
Index Ventures Venture Capital Minority 000 0000 000000 0
Lux Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial